The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5'-(T.sub.x)G.sub.xG.sub.xc.sub.sa.sub.sa.sub.sg.sub.sc.sub.sa.sub.st.sub- .sc.sub.sc.sub.sT.sub.xG.sub.xT-3' and 5'-(G.sub.x)T.sub.xT.sub.xa.sub.sc.sub.st.sub.sg.sub.sc.sub.sc.sub.st.sub- .st.sub.sc.sub.sT.sub.xT.sub.xA-3', wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript "s" designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript "x" designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.